J David Port
Overview
Explore the profile of J David Port including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Werahera P, Jasion E, Crawford E, La Rosa F, Lucia M, Van Bokhoven A, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2015 Jan;
2014:2165-8.
PMID: 25570414
Transrectal ultrasound guided prostate biopsies often fail to diagnose prostate cancer with 90% of cores reported as benign. Thus, it is desirable to target prostate cancer lesions while reducing the...
12.
Aleong R, Sauer W, Davis G, Murphy G, Port J, Anand I, et al.
JACC Heart Fail
. 2013 Oct;
1(4):338-344.
PMID: 24159564
Objectives: This study assessed the impact of bucindolol, a beta-blocker/sympatholytic agent, on the development of atrial fibrillation (AF) in advanced chronic heart failure with reduced left ventricular ejection fraction (HFREF)...
13.
OConnor C, Fiuzat M, Carson P, Anand I, Plehn J, Gottlieb S, et al.
PLoS One
. 2012 Oct;
7(10):e44324.
PMID: 23071495
Background: Pharmacogenetics involves complex interactions of gene products affecting pharmacodynamics and pharmacokinetics, but there is little information on the interaction of multiple genetic modifiers of drug response. Bucindolol is a...
14.
15.
Dockstader K, Nunley K, Karimpour-Fard A, Medway A, Nelson P, Port J, et al.
Physiol Genomics
. 2011 Sep;
43(23):1294-306.
PMID: 21954455
Several studies in humans or transgenic animals have reported that the 389 Arg or Gly polymorphic variation of the β1-adrenergic receptor (AR) is associated with differential responses to beta-blocker therapy...
16.
Port J, Walker L, Polk J, Nunley K, Buttrick P, Sucharov C
Physiol Genomics
. 2011 Jul;
43(19):1087-95.
PMID: 21771878
Analysis of changes in gene expression is an important means to define molecular differences associated with the phenotypic changes observed in response to myocardial infarction (MI). Several studies in humans...
17.
David Gerecht P, Taylor M, Port J
BMC Cell Biol
. 2010 Sep;
11:69.
PMID: 20843363
Background: A number of RNA binding proteins (BPs) bind to A+U rich elements (AREs), commonly present within 3'UTRs of highly regulated RNAs. Individual RNA-BPs proteins can modulate RNA stability, RNA...
18.
Port J, Sucharov C
J Cardiovasc Pharmacol
. 2010 Aug;
56(5):444-53.
PMID: 20729754
MicroRNAs (miRNAs, miRs) are short approximately 22-nucleotide noncoding RNAs that bind to messenger RNA transcripts and in doing so modulate cognate gene expression. In eukaryotes, miRNAs act primarily by causing...
19.
Bristow M, Murphy G, Krause-Steinrauf H, Anderson J, Carlquist J, Thaneemit-Chen S, et al.
Circ Heart Fail
. 2009 Nov;
3(1):21-8.
PMID: 19880803
Background: Adrenergic activation is an important determinant of outcomes in chronic heart failure. Adrenergic activity is regulated in part by prejunctional alpha(2C)-adrenergic receptors (ARs), which exhibit genetic variation in humans....
20.
Sucharov C, Bristow M, Port J
J Mol Cell Cardiol
. 2008 Jun;
45(2):185-92.
PMID: 18582896
MicroRNAs (miRNAs) are small, noncoding ~22-nucleotide regulatory RNAs that are key regulators of gene expression programs. Their role in the context of the cardiovascular system has only recently begun to...